Back to News
Market Impact: 0.25
DifGen Pharmaceuticals LLC Announces U.S. FDA Approval of Epinephrine Injection USP, 1 mg/mL, Single-Dose Vials
Source: PR Newswire
Healthcare & BiotechProduct LaunchesRegulation & LegislationCompany Fundamentals
DifGen Pharmaceuticals received approval to market the second generic version of Adrenalin Injection in the U.S., expanding its injectable-drug portfolio. The approval supports incremental portfolio growth and potential sales opportunities in specialty generics, though the article provides no revenue, pricing, launch-date, or market-share estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Japan’s corporate leaders sound alarm over weak yen — even dollar-earners are voicing concerns
- Fed hikes again - an AI-Picked insurer is still cashing in
- Congress passes sweeping US sanctions bill targeting Russia
- Berkshire May Boost Japan Trading House Holdings, Itochu Says
- House Passes Bill Allowing Trump Tariffs on Russian Oil Buyers
- Fed Rate Hike Looms as Retail Sales Surge